Designing new drugs that target protein interactions to fight diseases
Official title: Enabling Rational Design of Drug Targeting Protein-Protein Interactions with Physics-based Computational Modeling
Funded at Rochester Institute of Technology · NIH-10907574 · Data updated 2026-11-12
This study is exploring new medications that can change how proteins in our bodies interact, which could help create better treatments for cancer, genetic diseases, and infections, making them more effective for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rochester Institute of Technology NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | August 15, 2023 |
| Project end | July 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $185,000 |
| NIH project number | 5R16GM150512-02 |
| Project ID | NIH-10907574 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with cancer, genetic disorders, or infections that are resistant to current treatments.
✕Less likely to help
Patients with conditions unrelated to protein interactions or those who do not have access to advanced therapeutic options may not benefit from this research.
What this research studies
This research focuses on developing new drugs that can target the interactions between proteins, which are crucial for regulating cellular and viral behaviors. By using advanced computational modeling techniques, including machine learning and physics-based simulations, the project aims to predict how proteins interact and how these interactions can be modified by drugs. This approach could lead to innovative treatments for cancer, genetic diseases, and infections by disrupting harmful protein interactions. Patients may benefit from new therapies that are more effective against diseases caused by protein interaction imbalances.
Why it matters
Potential benefit: If successful, this research could lead to the development of groundbreaking therapies for cancer and infectious diseases.
How similar studies have gone: Other research has shown promise in targeting protein-protein interactions for drug development, indicating that this approach could be effective.
Where this research is happening
-
Rochester Institute of Technology
Rochester, United States Active
Researchers
- Principal investigator: Brini, Emiliano — Rochester Institute of Technology
- Study coordinator: Brini, Emiliano
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.